How long should you take and stop taking venetoclax/venetoclax?

Venetoclax/Venetoclax is a selective B-cell lymphoma 2 (BCL-2) inhibitor that has recently been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with 17p deletion chronic lymphocytic leukemia (CLL) who have received at least one prior therapy. The efficacy of venetoclax, which has been demonstrated as a single agent or in combination, appears to extend to other hematologic malignancies in which BCL-2 overexpression contributes to the development of tumors, including acute myeloid leukemia (AML).

However, there is no fixed answer to the question of how long it is appropriate to take and stop taking venetoclax, because it depends on a variety of factors, including the patient's specific condition, treatment response, physical condition, and doctor's advice. The pharmacokinetic and pharmacodynamic properties of venetoclax have been characterized in multiple clinical studies. Under low-fat conditions, plasma concentrations of venetoclax peak approximately 5 to 8 hours after administration, with exposure increasing 3 to 5-fold in the presence of food, with end-stage t1/2 between 1 and 2 hours in patients with CLL and AML.

Treatment with venetoclax is usually a long-term process, and patients need to continue taking the drug for a period of time to see obvious therapeutic effects. During this process, doctors will regularly evaluate the patient's condition and treatment effects, and adjust the treatment plan based on the evaluation results. If the patient's condition is effectively controlled and the patient is in good physical condition, the doctor may recommend gradually reducing the dose and eventually discontinuing the medication. However, if the patient's condition is unstable or at risk of recurrence, the doctor may recommend continuing the medication or adjusting the treatment regimen.